The Nasdaq-listed cancer drugs developer is up 43% in pre-market trading after promising shareholders special dividends worth more than its closing share price on Friday. Nasdaq-listed Merrimack Pharmaceuticals agreed to sell oncology treatments, including its pancreatic-cancer treatment Onivyde, to French drugmaker Ipsen for as much as $1.05 billion, including benchmark payments.